The monotherapy with HisDianthin‐EGF also caused a decrease in tumor volume (40.8 ± 61.3 mm3), which was a 51.7% average reduction when compared to placebo; however, treatment together with SO1861 resulted in a more than 13‐fold better efficacy. This evidence concerns the gene EGF and neoplasm.